Search results
Showing 3091 to 3105 of 9092 results
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
Details of the business expenses incurred by the board and senior management team in delivery of their duties.
IMI and H2020 Grant funded projects with NICE
Our guidance is developed by independent committees, including professionals and lay members, and consulted on by stakeholders.
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
Agenda and papers of the NICE public board meeting on 10 December 2025
Agenda and papers of the NICE public board meeting on 19 March 2025
Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.
Agenda and papers of the NICE public board meeting on 17 March 2022
NICE's equality, diversity, and inclusion roadmap and annual action plan - committed to creating a forward-looking, positive work culture where everyone can thrive.
Agenda and papers of the NICE public board meeting on 25 May 2022
Agenda and papers of the NICE public board meeting on 17 July 2024
Agenda and papers of the NICE public board meeting on 19 July 2023
Agenda and papers of the NICE public board meeting on 25 September 2024